30.57
-0.14 (-0.46%)
| 前收盘价格 | 30.71 |
| 收盘价格 | 30.99 |
| 成交量 | 2,499,003 |
| 平均成交量 (3个月) | 2,033,185 |
| 市值 | 4,853,276,672 |
| 市盈率 (P/E TTM) | 11.04 |
| 预期市盈率 (P/E Forward) | 23.98 |
| 价格/销量 (P/S) | 9.33 |
| 股市价格/股市净资产 (P/B) | 8.03 |
| 52周波幅 | |
| 利润日期 | 3 Nov 2025 |
| 营业毛利率 | 10.13% |
| 营业利益率 (TTM) | 7.13% |
| 稀释每股收益 (EPS TTM) | 0.250 |
| 季度收入增长率 (YOY) | 90.40% |
| 季度盈利增长率 (YOY) | -96.60% |
| 总债务/股东权益 (D/E MRQ) | 107.29% |
| 流动比率 (MRQ) | 4.02 |
| 营业现金流 (OCF TTM) | -61.02 M |
| 杠杆自由现金流 (LFCF TTM) | -87.64 M |
| 资产报酬率 (ROA TTM) | 7.26% |
| 股东权益报酬率 (ROE TTM) | 19.70% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | TG Therapeutics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | 1.5 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.5 |
| 平均 | 1.00 |
|
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 9.74% |
| 机构持股比例 | 63.22% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Congress Asset Management Co | 31 Dec 2025 | 1,922,410 |
| Hood River Capital Management Llc | 30 Sep 2025 | 1,552,788 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 49.00 (JP Morgan, 60.29%) | 购买 |
| 中 | 44.00 (43.93%) | |
| 低 | 39.00 (Goldman Sachs, 27.58%) | 保留 |
| 平均值 | 44.00 (43.93%) | |
| 总计 | 1 购买, 1 保留 | |
| 平均价格@调整类型 | 32.20 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Goldman Sachs | 15 Jan 2026 | 39.00 (27.58%) | 保留 | 30.71 |
| JP Morgan | 03 Nov 2025 | 49.00 (60.29%) | 购买 | 33.69 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| POWER SEAN A | 30.50 | - | 90,000 | 2,745,000 |
| WEISS MICHAEL S | 30.50 | - | 622,000 | 18,971,000 |
| 累积净数量 | 712,000 | |||
| 累积净值 ($) | 21,716,000 | |||
| 累积平均购买 ($) | 30.50 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| POWER SEAN A | 职员 | 08 Jan 2026 | 获得 (+) | 90,000 | 30.50 | 2,745,000 |
| WEISS MICHAEL S | 职员 | 08 Jan 2026 | 获得 (+) | 622,000 | 30.50 | 18,971,000 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合